文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

NEDD8激活酶抑制剂pevonedistat联合化疗治疗复发或难治性儿童实体瘤的1期研究(ADVL1615)

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
PubMed 文献 · Eur J Cancer · 2024-08-02

本研究为1期滚动6设计试验,旨在确定pevonedistat联合伊立替康和替莫唑胺在复发/难治性儿童实体瘤或中枢神经系统肿瘤中的推荐2期剂量(RP2D)。30例患者入组,最大耐受剂量未超过,RP2D为35 mg/m2(第1、3、5天给药),2/12(17%)患者在RP2D出现1周期剂量限制性毒性,2例部分缓解,6例延长疾病稳定(>6周期)。

要点

  • pevonedistat联合伊立替康/替莫唑胺在儿童实体瘤或中枢神经系统肿瘤中耐受良好。
  • 推荐2期剂量为pevonedistat 35 mg/m2,第1、3、5天给药,联合伊立替康/替莫唑胺。
  • RP2D组2/12(17%)患者出现1周期剂量限制性毒性,2例部分缓解,6例疾病稳定>6周期。

核心结论

  • pevonedistat联合伊立替康/替莫唑胺在儿童实体瘤或中枢神经系统肿瘤中耐受良好,RP2D为pevonedistat 35 mg/m2第1、3、5天联合伊立替康/替莫唑胺。

研究设计与样本

  • 1期研究采用滚动6设计,评估pevonedistat递增剂量联合标准剂量伊立替康和替莫唑胺,在复发/难治性实体瘤或中枢神经系统肿瘤儿童患者中进行。
  • 30例患者入组,所有患者均符合条件并可评估毒性;pevonedistat剂量水平1(15 mg/m2)、2(20 mg/m2)、3(25 mg/m2)和4(35 mg/m2)各入组6例,另在剂量水平4设扩展药代动力学队列。
  • 第1周期pevonedistat静脉给药于第1、8、10、12天,伊立替康(静脉,50 mg/m2)和替莫唑胺(口服,100 mg/m2)于28天周期的第8-12天给药;后续周期pevonedistat于第1、3、5天给药,伊立替康/替莫唑胺于21天周期的第1-5天给药。

主要发现

  • 最大耐受剂量未超过。
  • 在RP2D(35 mg/m2)治疗的12例患者中,2例(17%)出现1周期剂量限制性毒性。
  • 伊立替康不太可能影响pevonedistat的药代动力学。
  • 2例患者部分缓解,6例患者延长疾病稳定(>6周期)。

关键数值与推荐

  • pevonedistat的RP2D为35 mg/m2,第1、3、5天给药,联合伊立替康/替莫唑胺。
  • RP2D组1周期剂量限制性毒性发生率为2/12(17%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to determine the recommended Phase 2 dose (RP2D) of pevonedistat, a first in class inhibitor of NEDD8 activating enzyme, in combination with irinotecan (IRN) and temozolomide (TMZ) in children with cancer. METHODS: This Phase 1 study used a rolling 6 design to evaluate escalating doses of pevonedistat in combination with standard doses of IRN and TMZ in pediatric patients with recurrent/refractory solid or CNS tumors. During cycle 1, pevonedistat was administered intravenously on days 1, 8, 10, and 12, with IRN (IV, 50 mg/m2) and TMZ (orally, 100 mg/m2), on days 8-12 of a 28-day cycle. In subsequent cycles, pevonedistat was administered on days 1, 3, and 5, with IRN/TMZ on days 1-5 of a 21-day cycle. RESULTS: Thirty patients enrolled; all were eligible and evaluable for toxicity. Six patients each enrolled on pevonedistat dose levels (DL) 1 (15 mg/m2), 2 (20 mg/m2), 3 (25 mg/m2) and 4 (35 mg/m2) as well as an expanded pharmacokinetic (PK) cohort at DL4. The maximum tolerated dose (MTD) was not exceeded. 2/12 (17 %) patients treated at the RP2D (35 mg/m2) experienced a cycle 1 dose limiting toxicity (DLT). IRN is unlikely to affect the pharmacokinetics of pevonedistat. Two patients had a partial response and 6 patients had prolonged stable disease (> 6 cycles). CONCLUSIONS: Pevonedistat in combination with IRN/TMZ is well tolerated in children with solid or CNS tumors. The RP2D of pevonedistat is 35 mg/m2 on days 1, 3, 5 in combination with IRN/TMZ.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Foster JH, Reid JM, Minard C, et al. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024. PMID: 39096851. doi:10.1016/j.ejca.2024.114241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。